A carregar...
Publicação
Nirsevimab effectiveness against RSV-related hospitalisations in children under 24 months
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 451.16 KB | Adobe PDF |
Orientador(es)
Resumo(s)
We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)-related hospitalisation in eligible children (< 2 years) using a test-negative case–control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV-positive. Adjusted NE against RSV-related hospitalisation was 78.5% (95%CI: 59.3–89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.
Descrição
Publisher Copyright: © 2025 The Author(s). Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Palavras-chave
children effectiveness nirsevimab RSV-related hospitalisations Epidemiology Pulmonary and Respiratory Medicine Public Health, Environmental and Occupational Health Infectious Diseases SDG 3 - Good Health and Well-being